{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:32:21Z","timestamp":1760239941532,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.hoc.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T21:05:22Z","timestamp":1656104722000},"page":"853-864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene Therapy for Pediatric Neurologic Disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Lauren","family":"Jimenez-Kurlander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine N.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.hoc.2022.05.003_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14712598.2019.1607837","article-title":"An update on gene therapy for lysosomal storage disorders","volume":"19","author":"Nagree","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"10.1016\/j.hoc.2022.05.003_bib2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1089\/hum.2017.160","article-title":"Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future","volume":"28","author":"Piguet","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.hoc.2022.05.003_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1208\/s12249-021-02144-1","article-title":"Multi-disciplinary Approach for Drug and Gene Delivery Systems to the Brain","volume":"23","author":"Ndemazie","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.hoc.2022.05.003_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1566523221666210728141924","article-title":"Clinical Development of Cell Therapies to Halt Lysosomal Storage Diseases: Results and Lessons Learned","volume":"22","author":"Graceffa","year":"2022","journal-title":"Curr Gene Ther"},{"issue":"6","key":"10.1016\/j.hoc.2022.05.003_bib5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.hoc.2022.05.003_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.seminhematol.2004.07.007","article-title":"Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable","volume":"41","author":"von Kalle","year":"2004","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2022.05.003_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"R1","key":"10.1016\/j.hoc.2022.05.003_bib8","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1093\/hmg\/ddv457","article-title":"Gene therapy for lysosomal storage disorders: a good start","volume":"25","author":"Biffi","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"10","key":"10.1016\/j.hoc.2022.05.003_bib9","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1089\/hum.2019.190","article-title":"Gene-Based Approaches to Inherited Neurometabolic Diseases","volume":"30","author":"Poletti","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.hoc.2022.05.003_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10545-007-0516-z","article-title":"Molecular and clinical aspects of peroxisomal diseases","volume":"30","author":"Shimozawa","year":"2007","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.hoc.2022.05.003_bib11","series-title":"Fabry disease: Perspectives from 5 Years of FOS","article-title":"Epidemiology of lysosomal storage diseases: an overview","author":"Fuller","year":"2006"},{"issue":"1","key":"10.1016\/j.hoc.2022.05.003_bib12","first-page":"77","article-title":"The uptake of enzymes into lysosomes: an overview","volume":"16","author":"Neufeld","year":"1980","journal-title":"Birth Defects Orig Artic Ser"},{"issue":"6","key":"10.1016\/j.hoc.2022.05.003_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/0883073819828587","article-title":"Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities","volume":"34","author":"Maegawa","year":"2019","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.hoc.2022.05.003_bib14","doi-asserted-by":"crossref","first-page":"661928","DOI":"10.3389\/fncel.2021.661928","article-title":"Canavan Disease as a Model for Gene Therapy-Mediated Myelin Repair","volume":"15","author":"Lotun","year":"2021","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"10.1016\/j.hoc.2022.05.003_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ymthe.2021.04.003","article-title":"Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges","volume":"30","author":"Miccio","year":"2022","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.hoc.2022.05.003_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(21)00071-5","article-title":"Gene therapy for spinal muscular atrophy: hope and caution","volume":"20","author":"Goemans","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.hoc.2022.05.003_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/mp.53.4.173","article-title":"Retroviral vectors","volume":"53","author":"Kurian","year":"2000","journal-title":"Mol Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2022.05.003_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40259-018-0261-x","article-title":"Codon Optimization in the Production of Recombinant Biotherapeutics: Potential Risks and Considerations","volume":"32","author":"Mauro","year":"2018","journal-title":"BioDrugs"},{"issue":"17","key":"10.1016\/j.hoc.2022.05.003_bib19","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2022.05.003_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1474-4422(07)70177-1","article-title":"Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study","volume":"6","author":"Mahmood","year":"2007","journal-title":"Lancet Neurol"},{"issue":"26","key":"10.1016\/j.hoc.2022.05.003_bib21","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJM199006283222607","article-title":"Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation","volume":"322","author":"Aubourg","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2022.05.003_bib22","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1073\/pnas.0306431101","article-title":"Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein","volume":"101","author":"Asheuer","year":"2004","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5954","key":"10.1016\/j.hoc.2022.05.003_bib23","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.hoc.2022.05.003_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-12-386509-0.00010-7","article-title":"Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy","volume":"507","author":"Cartier","year":"2012","journal-title":"Methods Enzymol"},{"year":"2021","series-title":"Bluebird bio Announces FDA Priority review of Biologics License application for\u00a0eli-cel gene therapy for cerebral adrenoleukodystrophy (CALD) in patients without a Matched Sibling donor","key":"10.1016\/j.hoc.2022.05.003_bib25"},{"issue":"5","key":"10.1016\/j.hoc.2022.05.003_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals","volume":"13","author":"Wang","year":"2011","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.hoc.2022.05.003_bib27","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.hoc.2022.05.003_bib28","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00431-009-0937-9","article-title":"Fabry disease in children and the effects of enzyme replacement treatment","volume":"168","author":"Pintos-Morell","year":"2009","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.hoc.2022.05.003_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.omtm.2017.05.003","article-title":"Lentivector Iterations and Pre-Clinical Scale-Up\/Toxicity Testing: Targeting Mobilized CD34(+) Cells for Correction of Fabry Disease","volume":"5","author":"Huang","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.hoc.2022.05.003_bib30","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2022.05.003_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/humu.22919","article-title":"Mutation Update of ARSA and PSAP Genes Causing Metachromatic Leukodystrophy","volume":"37","author":"Cesani","year":"2016","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.hoc.2022.05.003_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10545-007-0540-z","article-title":"Enzyme, cell and gene-based therapies for metachromatic leukodystrophy","volume":"30","author":"Sevin","year":"2007","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"8","key":"10.1016\/j.hoc.2022.05.003_bib33","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1172\/JCI200419205","article-title":"Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells","volume":"113","author":"Biffi","year":"2004","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.hoc.2022.05.003_bib34","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J\u00a0Clin Invest"},{"issue":"10043","key":"10.1016\/j.hoc.2022.05.003_bib35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2022.05.003_bib36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.hoc.2022.05.003_bib37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.isci.2019.04.036","article-title":"CRISPR\/Cas9 Genome Engineering in Engraftable Human Brain-Derived Neural Stem Cells","volume":"15","author":"Dever","year":"2019","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.hoc.2022.05.003_bib38","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/mt.2012.153","article-title":"Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease","volume":"20","author":"Rafi","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2022.05.003_bib39","doi-asserted-by":"crossref","first-page":"14013","DOI":"10.1038\/mtm.2014.13","article-title":"Development of Gene Transfer for Induction of Antigen-specific Tolerance","volume":"1","author":"Sack","year":"2014","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:18:13Z","timestamp":1760185093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858822000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0889858822000387"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2022.05.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Therapy for Pediatric Neurologic Disease","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}